JOHNSON & JOHNSON is 321.1x more valuable than Stoke Therapeutics, Inc. by market capitalization ($573.98 B vs $1.79 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | STOK | JNJ |
|---|---|---|
| Market cap | $1.79 B | $573.98 B |
| US-listed rank | #2180 | #20 |
| Revenue (latest FY) | $184.42M | $94.19B |
| Net income (latest FY) | -$6.88M | $26.80B |
| Net margin | -3.7% | 28.5% |
| P/E (trailing FY) | - | 21.4 |
| SEC filings | 588 | 984 |
JOHNSON & JOHNSON is 321.1x more valuable than Stoke Therapeutics, Inc. by market capitalization ($573.98 B vs $1.79 B).
In their latest fiscal years, Stoke Therapeutics, Inc. reported $184.42M in revenue while JOHNSON & JOHNSON reported $94.19B.
Full pages: Stoke Therapeutics, Inc. and JOHNSON & JOHNSON, or browse the full rankings.